论文部分内容阅读
目的研究131I标记的rituximab对CD20高表达的B细胞淋巴瘤细胞的生物学效应,为放射免疫导向治疗提供实验依据。方法 IODO-GEN法将131I标记于抗CD20单抗rituximab,用Annexin Ⅴ-FITC／PI双染法检测131I-rituximab对 Raji细胞的诱导凋亡作用,PI染色法检测细胞周期分布。结果 Annexin Ⅴ-FITC／PI双染法检测凋亡率:131I-rituximab组凋亡率为51．99％,131I组为42．71％,rituximab组为29．42％,对照组为26．17％。对照组和rituximab组凋亡率明显低于131I 组和131I-rituximab组(P<0．05)。PI染色法对比各组的凋亡率(亚二倍体峰):131I-rituximab组细胞凋亡率为4．32％,131I组为 1．47％,rituximab组为1．39％,对照组仅0．37％,131I-rituximab组凋亡率明显高于其他各组(P<0．05)。131I-rituximab组Raji细胞周期发生变化,细胞大部分被阻滞于G1／G2期。结论 131I-rituximab能够调控Raji细胞的细胞周期并诱导其凋亡,从而抑制Raji细胞增殖。
Objective To investigate the biological effects of 131I-labeled rituximab on CD20-overexpressing B cell lymphoma cells and provide experimental evidence for radioimmunotherapy. Methods 131I was labeled with anti-CD20 mAb rituximab by IODO-GEN method. The apoptosis induced by 131I-rituximab was detected by Annexin Ⅴ-FITC / PI double staining. The cell cycle distribution was detected by PI staining. Results Annexin Ⅴ-FITC / PI double staining assay showed that the apoptotic rate was 51.99% in 131I-rituximab group, 42.71% in 131I group, 29.42% in rituximab group and 26.17 in control group %. The apoptosis rate in control group and rituximab group was significantly lower than that in 131I group and 131I-rituximab group (P <0.05). PI staining was used to compare the apoptotic rate (sub-diploid peak) in each group: the apoptotic rate in 131I-rituximab group was 4.32%, in 131I group was 1.47%, in rituximab group was 1.39% Only 0.37%, the apoptosis rate of 131I-rituximab group was significantly higher than other groups (P <0.05). 131I-rituximab group Raji cell cycle changes, the majority of cells were arrested in the G1 / G2 phase. Conclusion 131I-rituximab can regulate the cell cycle of Raji cells and induce their apoptosis, thereby inhibiting the proliferation of Raji cells.